Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDLGRO)

Drug Name

Aramchol Drug Info

Synonyms

Stearoyl CoA desaturase-1 inhibitor (oral, liver/lipid metabolism diseases), Galmed

Indication

Disease Entry	ICD 11	Status	REF
Lipid metabolism disorder	5C52.Z	Phase 2/3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Acyl-CoA desaturase (SCD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isoxyl	DMJL10P	Bacterial infection	1A00-1C4Z	Approved	[3]
MK-8245	DMG6KXB	Type-2 diabetes	5A11	Phase 2	[4]
Sterculic acid	DM1PMR3	Discovery agent	N.A.	Investigative	[5]
ISIS 147919	DMTE3FJ	Discovery agent	N.A.	Investigative	[6]
2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide	DMJA5Y4	Discovery agent	N.A.	Investigative	[7]
MF-152	DMBLUSA	Discovery agent	N.A.	Investigative	[8]
CVT-12012	DMOCKMZ	Diabetic complication	5A2Y	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02279524) A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH. U.S. National Institutes of Health.
2	The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1.
3	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
4	Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011 Jul 28;54(14):5082-96.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	US patent application no. 7,132,529, Antisense modulation of stearoyl-CoA desaturase expression.
7	Thiazole analog as stearoyl-CoA desaturase 1 inhibitor. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5214-7.
8	SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1593-7.
9	Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4070-4.